Proteomic comparison of oligodendrogliomas with and without 1pLOH

Cancer Biology and Therapy

Volumn 6, Issue 3, 2007, Pages 391-396

  Okamoto, Hiroaki ^a,b   Li, Jie ^a   Gläsker, Sven ^a   Vortmeyer, Alexander O ^a   Jaffe, Howard ^a   Robison, R Aaron ^a   Bogler, Oliver ^c   Mikkelsen, Tom ^c   Lubensky, Irina A ^a   Oldfield, Edward H ^a   Zhuang, Zhengping ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b SAGA UNIVERSITY   (Japan)

^c HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; DNA BINDING PROTEIN; NUCLEOSIDE DIPHOSPHATE KINASE A; PROTEIN EB1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CHEMOSENSITIVITY; CHROMOSOME 1; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; OLIGODENDROGLIOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

EID: 34548218234     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.3.3731     Document Type: Article

References (44)

1. Mork SJ, Lindegaard KF, Halvorsen TB, Lehman EH, Solgaard T, Hatlevoll R, Harvei S, Ganz J. Oligodendroglioma: incidence and biological behavior in a defined population. J Neurosurg 1985; 63:881-9.
2. Reifenberger G, Kros JM, Burger PC, Louis DN, Collins VP. Tumours of the Nervous System 2000; 56-61.
3. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90:1473-9.
4. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000; 18:636-45.
5. Kujas M, Lejeune J, Benouaich-Amiel A, Criniere E, Laigle-Donadey F, Marie Y, Mokhtari K, Polivka M, Bernier M, Chretien F, Couvelard A, Capelle L, Duffau H, Cornu P, Broet P, Thillet J, Carpentier AF, Sanson M, Hoang-Xuan K, Delattre JY. Chromosome 1p loss: A favorable prognostic factor in low-grade gliomas. Ann Neurol 2005; 58:322-6.
6. Husemann, K, Wolter M, Buschges R, Bostrom J, Sabel M, Reifenberger G. Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. J Neuropathol Exp Neurol 1999; 58:1041-50.
7. Mai, M, Huang H, Reed C, Qian C, Smith JS, Alderete B, Jenkins R, Smith DI, Liu W. Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions. Genomics 1998; 51:359-63.
8. Reifenberger G, Louis DN. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 2003; 62:111-26.
9. Mukasa, A. Ueki K, Matsumoto S, Tsutsumi S, Nishikawa R, Fujimaki T, Asai A, Kirino T, Aburatani H. Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. Oncogene 2002; 21:3961-8.
10. Iwadate Y, Sakaida T, Hiwasa T, Nagai Y, Ishikura H, Takiguchi M, Yamaura A. Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 2004; 64:2496-501.
11. Furuta M, Weil RJ, Vortmeyer AO, Huang S, Lei J, Huang TN, Lee YS, Bhowmick DA, Lubensky IA, Oldfield EH, Zhuang Z. Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene 2004; 23:6806-14.
12. Chumbalkar VC, Subhashini C, Dhople VM, Sundaram CS, Jagannadham MV, Kumar KN, Srinivas PN, Mythili R, Rao MK, Kulkarni MJ, Hegde S, Hegde AS, Samual C, Santosh V, Singh L, Sirdeshmukh R. Differential protein expression in human gliomas and molecular insights. Proteomics 2005; 5:2702.
13. Vogel TW, Zhuang Z, Li J, Okamoto H, Furuta M, Lee YS, Zeng W, Oldfield EH, Vortmeyer AO, Weil RJ. Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme. Clin Cancer Res 2005;11:3624-32.
14. Thornalley, PJ. Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy. Biochem Soc Trans 2003; 31:1372-7.
15. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N.Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003; 94:15-21.
16. Sakamoto H, Sakamoto H, Mashima T, Kizaki A, Dan S, Hashimoto Y, Naito M, Tsuruo T. Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood 2000; 95:3214-8.
17. Creighton DJ, Zheng ZB, Holewinski R, Hamilton DS, Eiseman JL. Glyoxalase I inhibitors in cancer chemotherapy. Biochem Soc Trans 2003; 31:1378-82.
18. Zhang B, Zhang Y, Dagher MC, Shacter E. Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Cancer Res 2005; 65:6054-62.
19. MacKeigan JP, Clements CM, Lich JD, Pope RM, Hod Y, Ting JP. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIalpha. Cancer Res 2003; 63:6928-34.
20. Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, Petricoin EF 3rd. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2002; 2:76-84.
21. Sinha P, Kohl S, Fischer J, Hutter G, Kern M, Kottgen E, Dietel M, Lage H, Schnolzer M, Schadendorf D. Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis 2000; 21:3048-57.
22. Westley BR, May FE. Prognostic value of cathepsin D in breast cancer. Br J Cancer 1999; 79:189-90.
23. Liaudet-Coopman E, Beaujouin M, Derocq D, Garcia M, Glondu-Lassis M, Laurent-Matha V, Prebois C, Rochefort H, Vignon F. Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett 2006; 237:167-79.
24. Fukuda ME, Iwadate Y, Machida T, Hiwasa T, Nimura Y, Nagai Y, Takiguchi M, Tanzawa H, Yamaura A, Seki N. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res 2005; 65:5190-4.
25. Sivaparvathi M, Sawaya R, Chintala SK, Go Y, Gokaslan ZL, Rao JS. Expression of cathepsin D during the progression of human gliomas. Neurosci Lett 1996; 208171-4.
26. Schnier JB, Nishi K, Monks A, Gorin FA, Bradbury EM. Inhibition of glycogen phosphorylase (GP) by CP-91,149 induces growth inhibition correlating with brain GP expression. Biochem Biophys Res Commun 2003; 309:126-34.
27. Tashima S, Shimada S, Yamaguchi K, Tsuruta J, Ogawa M. Expression of brain-type glycogen phosphorylase is a potentially novel early biomarker in the carcinogenesis of human colorectal carcinomas. Am J Gastroenterol 2000; 95:255-63.
28. Godfried MB, Veenstra M, Sluis P, Boon K, Asperen R, Hermus MC, Schaik BD, Voute TP, Schwab M, Versteeg R, Caron HN. The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2. Oncogene 2002; 21:2097-101.
29. Heimann R, Ferguson DJ, Hellman S. The relationship between nm23, angiogenesis, and the metastatic proclivity of node-negative breast cancer. Cancer Res 1998; 58:2766-71.
30. Takino H, Herman V, Weiss M, Melmed S. Purine-binding factor (nm23) gene expression in pituitary tumors: marker of adenoma invasiveness. J Clin Endocrinol Metab 1995; 80:1733-8.
31. Iizuka N, Hirose K, Noma T, Hazama S, Tangoku A, Hayashi H, Abe T, Yamamoto K, Oka M. The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma. Br J Cancer 1999; 81469-75.
32. Ferguson AW, Flatow U, MacDonald NJ, Larminat F, Bohr VA, Steeg PS. Increased sensitivity to cisplatin by nm23-transfected tumor cell lines. Cancer Res 1996; 56:2931-5.
33. Kwiatkowski DJ. Functions of gelsolin: motility, signaling, apoptosis, cancer. Curr Opin Cell Biol 1999; 11:103-8.
34. McGough AM, Staiger CJ, Min JK, Simonetti KD. The gelsolin family of actin regulatory proteins: modular structures, versatile functions. FEBS Lett 2003; 552:75-81.
35. Kim JH, Choi YK, Kwon HJ, Yang HK, Choi JH, Kim DY. Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1. J Gastroenterol Hepatol 2004; 19:218-24.
36. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M, Nijkamp W, Weigelt B, Agami R, Ge W, Cavet G, Linsley PS, Beijersbergen RL, Bernards R. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004; 428:431-7.
37. Tanaka J, Sobue K. Localization and characterization of gelsolin in nervous tissues: gelsolin is specifically enriched in myelin-forming cells. J Neurosci 1994; 14:1038-52.
38. Lena JY, Legrand C, Faivre-Sarrailh C, Sarlieve LL, Ferraz C, Rabie A. High gelsolin content of developing oligodendrocytes. Int J Dev Neurosci 1994; 12:375-86.
39. Sarmiere PD, Bamburg JR. Regulation of the neuronal actin cytoskeleton by ADF/cofilin. J Neurobiol 2004; 58:103-17.
40. Fox MA, Afshari FS, Alexander JK, Colello RJ, Fuss B. Growth conelike sensorimotor structures are characteristic features of postmigratory, premyelinating oligodendrocytes. Glia 2005; 53:563-6.
41. Morrison EE, Wardleworth BN, Askham JM, Markham AF, Meredith DM. EB1, a protein which interacts with the APC tumour suppressor, is associated with the microtubule cytoskeleton throughout the cell cycle. Oncogene 1998; 17:3471-7.
42. Bhat RV, Axt KJ, Fosnaugh JS, Smith KJ, Johnson KA, Hill DE, Kinzler KW, Baraban JM. Expression of the APC tumor suppressor protein in oligodendroglia. Glia 1996; 17:169-74.
43. Pfeiffer B, Elmer K, Roggendorf W, Reinhart PH, Hamprecht B. Immunohistochemical demonstration of glycogen phosphorylase in rat brain slices. Histochemistry 1990; 94:73-80.
44. Pfeiffer B, Buse E, Meyermann R, Rocha MJ, Hamprecht B. Glycogen phosphorylase activity and immunoreactivity during pre- and postnatal development of rat brain. Histochemistry 1993; 100:265-70.